Immuneering/$IMRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Immuneering
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
- Ticker
- $IMRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 65
- Headquarters
- Cambridge, United States
- Website
- immuneering.com
Immuneering Metrics
BasicAdvanced
$238M
-
-$1.03
0.46
-
Price and volume
Market cap
$238M
Beta
0.46
52-week high
$8.48
52-week low
$3.35
Average daily volume
766K
Financial strength
Current ratio
13.966
Quick ratio
13.474
Long term debt to equity
0.018
Total debt to equity
0.021
Profitability
EBITDA (TTM)
-73.519
Management effectiveness
Return on assets (TTM)
-21.80%
Return on equity (TTM)
-33.53%
Valuation
Price to book
1.41
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
-3.854
Free cash flow yield (TTM)
-25.95%
Free cash flow per share (TTM)
-0.955
Growth
Earnings per share change (TTM)
-41.51%
3-year earnings per share growth (CAGR)
-18.01%
What the Analysts think about Immuneering
Analyst ratings (Buy, Hold, Sell) for Immuneering stock.
Analyst projections of the future price of Immuneering stock.
Immuneering Financial Performance
Revenues and expenses
Immuneering Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Immuneering
Fund name | Fund size | $IMRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.